

Pneumonia: diagnosis and management (update) Committee meeting 11 Day 1

Date: 08.01.2025

Location: Virtual (Zoom)

Minutes: Final

Committee members present:	
Tessa Lewis (Chair)	Present for notes 1 – 8
Srini Bandi	Present for notes 1 – 3
Tom Bewick	Present for notes 1 – 8
Dan Furmedge	Present for notes 1 – 8
Saira Hague	Present from partway through item 2 - 6
Alastair Hay	Present for notes 1 – 8
Jennifer Head	Present for notes 1 – 8
Dan Horner	Present from partway through item 2 - 6
Philip Howard	Present for notes 1 – 8
Marisa Lanzman	Present for notes 1 – 5
Paddy McMaster	Present for notes 1 – 8
Mitul Patel	Present for notes 1 – 8
Carole Pitkeathley	Present for notes 1 – 5 and 8
Kathryn Thomas	Present from partway through item 3 – 8
Avril Tucker	Present from partway through item 2 – 5 and 8
Caroline Ward	Present for notes 1 – 8
Dan Wootton	Present for notes 1 – 6

In attendance:		
Steph Armstrong	Senior Health Economist	Present for notes 1 – 8
Saoussen Ftouh	Senior Technical Analyst	Present for notes 1 – 8
Edgar Masanga	Business Analyst, Resource Impact Assessment	Present for notes 1 – 8
Adam O’Keefe	Project Manager	Present for notes 1 – 8
Joanna Perkin	Senior Guidance Content Designer	Present for notes 1 – 8
Louise Picton	Senior Medicines Adviser	Present for notes 1 – 2
Robby Richey	Topic Lead	Present for notes 1 – 8

Eric Slade	Health Economics Adviser	Present for notes 1 – 8
Hannah Stockton	Technical Analyst	Present for notes 1 – 8
Eileen Taylor (Observing)	Technical Analyst	Present for notes 1 – 8
Michellie Young	Technical Analyst	Present for notes 1 – 8

Apologies:

Sumiah Al-Azeib	Committee member
Joy Okafor	Committee member
Martin Williams	Committee member

1. Welcome and introductions

The Chair welcomed Committee members and attendees to day one of the eleventh meeting on Pneumonia: diagnosis and management (update). The Committee members and attendees introduced themselves. The Chair informed the Committee that apologies had been received. These are noted above.

The minutes of the previous meeting were then confirmed as a true and accurate record, subject to some minor amendments.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were the diagnosis and management of Pneumonia. The Chair asked everyone to verbally declare any new interests. The following new interest was declared:

Name	Job title	Declarations of Interest, date declared	Type of interest	Decision taken
Philip Howard	Consultant Pharmacist	Co-author: <i>Characteristics, risk factors and clinical impact of penicillin and other antibiotic allergies in adults in the UK General Practice: a population-based cohort study - ScienceDirect</i>	Non-financial professional and personal	Non-Specific Declare and participate
Philip Howard	Consultant Pharmacist	Co-author: <i>Assessing the Value of New Antimicrobials:</i>	Non-financial professional	Non-Specific

		<i>Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England Applied Health Economics and Health Policy</i>	and personal	Declare and participate
--	--	--	--------------	-------------------------

The Chair and a senior member of the Developer's team advised that neither these new nor any previously declared interests would prevent attendees from fully participating in the meeting.

2. Review Question 5.1: Are shorter durations of antibiotic treatment effective and cost-effective at treating babies, children and young people with community acquired pneumonia compared to longer treatment courses?

The group revisited recommendations drafted at earlier meetings, assisted the NICE team in resolving any outstanding queries and confirmed it was happy to proceed to public consultation with the recommendations as drafted. The group discussed potential research recommendations and any inequalities considerations in this area.

3. Review Question 7.1: What advice should be given to adults or parents/carers of babies, children, young people about what symptoms and duration of symptoms can be expected following treatment for community- or hospital-acquired pneumonia, and when should people be advised to consult or re-consult a GP?

The group revisited recommendations drafted at earlier meetings, assisted the NICE team in resolving any outstanding queries and confirmed it was happy to proceed to public consultation with the recommendations as drafted. The group discussed potential research recommendations and any inequalities considerations in this area.

4. Review Question 6.1: In people with community- or hospital-acquired pneumonia what is the clinical effectiveness and cost effectiveness of corticosteroid treatment in addition to antibiotic treatment compared with antibiotic treatment alone? Adults & Children

The group revisited recommendations drafted at earlier meetings. It discussed with NICE some outstanding queries but agreed further discussions were required before progressing draft recommendations in this area.

5. Review Question 6.2: In people in hospital with community- or hospital-acquired pneumonia, what is the clinical and cost effectiveness of 1 type of

non-invasive respiratory support (for example, non-invasive ventilation or continuous positive airway pressure) compared with another type of non-invasive respiratory support or usual care?

The group revisited recommendations drafted at earlier meetings, assisted the NICE team in resolving any outstanding queries and confirmed it was happy to proceed to public consultation with the recommendations as drafted. The group discussed potential research recommendations and any inequalities considerations in this area.

6. Queries arising from editing process (unscheduled item as ahead of schedule)

Hannah Stockton, Technical Analyst sought committee input to queries on the draft recommendations arising from the editing process.

7. Research recommendations prioritisation (unscheduled item as ahead of schedule)

Hannah Stockton, Technical Analyst led a session scheduled for day 2, beginning to revisit and prioritise the research recommendations drafted during development of the guideline to date.

8. AOB and next steps

There was no other business. The Chair reminded the group that day two of the meeting is scheduled to commence at 10:00 on 9 January 2025, thanked those present and closed the meeting.

Pneumonia: diagnosis and management (update) Committee meeting 11 Day 2

Date: 09.01.2025

Location: Virtual (Zoom)

Minutes: Draft

Committee members present:		
Tessa Lewis (Chair)		Present for notes 1 – 7
Srini Bandi		Present for notes 1 – 3
Tom Bewick		Present for notes 2 – 7
Dan Furmedge		Present from partway through item 3
Saira Hague		Present for notes 1 – 7
Jennifer Head		Present for notes 1 – partway through item 3
Dan Horner		Present for notes 1 – 7
Marisa Lanzman		Present for notes 1 – 7
Paddy McMaster		Present for notes 1 – 7
Mitul Patel		Present for notes 1 – 7
Carole Pitkeathley		Present for notes 1 – 7
Kathryn Thomas		Present for notes 1 – 7
Avril Tucker		Present for notes 1 – 7
Martin Williams		Present from partway through item 3
Dan Wooton		Present for notes 1 – 7

In attendance:		
Steph Armstrong	Senior Health Economist	Present for notes 1 – 7
Saoussen Ftouh	Senior Technical Analyst	Present for notes 1 – 7
Edgar Masanga	Business Analyst, Resource Impact Assessment	Present For notes 1 – 3
Adam O’Keefe	Project Manager	Present for notes 1 – 7
Joanna Perkin	Senior Guidance Content Designer	Present for notes 1 – 7
Robby Richey	Topic Lead	Present for notes 1 – 2 and 4 – 7
Eric Slade	Health Economics Adviser	Present for notes 1 – 7

Hannah Stockton	Technical Analyst	Present for notes 1 – 7
Michellie Young	Technical Analyst	Present for notes 1 – 2 and 4 – 7

Apologies:

Sumiah Al-Azeib	Committee member
Alastair Hay	Committee member
Philip Howard	Committee member
Joy Okafor	Committee member
Caroline Ward	Committee member

1. Welcome and introductions

The Chair welcomed Committee members and attendees to day two of the eleventh meeting on Pneumonia: diagnosis and management (update). The Committee members and attendees introduced themselves. The Chair informed the Committee that apologies had been received. These are noted above.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were the diagnosis and management of Pneumonia. The Chair asked everyone to verbally declare any new interests. No new interests were declared.

The Chair and a senior member of the Developer's team advised that no previously declared interests would prevent attendees from fully participating in the meeting.

2. Review Question RQ4.2: What are the most effective and cost-effective microbiological tests or combination of tests at presentation in secondary care to inform treatment decisions in people with suspected community-acquired pneumonia or suspected hospital-acquired pneumonia?

The group revisited recommendations drafted at earlier meetings, assisted the NICE team in resolving any outstanding queries and confirmed it was happy to proceed to public consultation with the recommendations as drafted. The group discussed potential research recommendations and any inequalities considerations in this area.

3. Research recommendations prioritisation

Hannah Stockton, Technical Analyst, continued the session begun the previous day to finalise and prioritise research recommendations drafted by the committee during development of this guideline update.

4. Review Question 1.1: In babies, children, and young people presenting with

a suspected lower respiratory tract infection or suspected community-acquired pneumonia in primary care, what is the most accurate and cost-effective outcome prediction tool to identify under 18s whose outcome will be improved by referral to hospital?

The group discussed and agreed research recommendations in this area.

5. Review Question 2.2: In people with suspected community-acquired pneumonia (presenting to an emergency care setting) what is the most accurate and cost-effective outcome prediction tool with or without the use of biomarkers or oxygen saturation monitoring, to stratify patients at first presentation according to who would be suitable for a particular care pathway?

The group discussed and agreed research recommendations in this area.

6. Guideline amalgamation discussion

Joanna Perkin, Senior Guidance Content Designer, lead a session on the amalgamation of the current guidelines into this update, checking with the committee the new headings and flow of the guideline.

7. AOB and next steps

There was no other business. Adam O’Keefe, Project Manager outlined next steps to consultation before the Chair thanked those present and closed the meeting.

Date of next meeting: Committee meeting 12: TBC

Location of next meeting: TBC